AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11783824 — intervention group
Group type: EXPERIMENTAL
Intervention: Other interventions (unspecified)
Number of subjects: 21
Study 9338537 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of terfenadine (120 mg) and ranitidine (300 mg)
Number of subjects: 121
Study 9338537 — intervention group
Group type: EXPERIMENTAL
Intervention: Terfenadine alone (120 mg)
Number of subjects: 121
Study 9338537 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 121
Study 9338537 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of terfenadine and ranitidine
Number of subjects: 121
Study 9338537 — intervention group
Group type: EXPERIMENTAL
Intervention: Terfenadine alone
Number of subjects: 121
Study 8177984 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated measurements of covariates
Number of subjects: 0
Study 3108622 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous nasoenteric formula infusion
Number of subjects: 4
Study 3108622 — intervention group
Group type: COMPARATOR
Intervention: Intermittent nasoenteric formula infusion
Number of subjects: 4
Study 31866373 — intervention group
Group type: EXPERIMENTAL
Intervention: Hallux valgus group (HVA >20°, IMA >9°)
Number of subjects: 213
Study 31866373 — intervention group
Group type: COMPARATOR
Intervention: Control group (HVA <15°, IMA <9°)
Number of subjects: 213
Study 31866373 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 213
Study 30843450 — intervention group
Group type: EXPERIMENTAL
Intervention: Vortioxetine 10 mg/day
Number of subjects: 286
Study 30843450 — intervention group
Group type: EXPERIMENTAL
Intervention: Vortioxetine 20 mg/day
Number of subjects: 286
Study 30843450 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 286
Study 29070467 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic surgery (group A)
Number of subjects: 80
Study 29070467 — intervention group
Group type: COMPARATOR
Intervention: Open surgery (group B)
Number of subjects: 80
Study 26324315 — intervention group
Group type: EXPERIMENTAL
Intervention: Bedoradrine (1200 μg)
Number of subjects: 167
Study 26324315 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 167
Study 23993034 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct current electrical stimulation
Number of subjects: 1381
Study 23993034 — intervention group
Group type: EXPERIMENTAL
Intervention: Capacitive coupling (CC) electrical stimulation
Number of subjects: 1381
Study 23993034 — intervention group
Group type: EXPERIMENTAL
Intervention: Inductive coupling electrical stimulation
Number of subjects: 1381
Study 22254404 — intervention group
Group type: EXPERIMENTAL
Intervention: FES-induced cycling
Number of subjects: 0
Study 22254404 — intervention group
Group type: COMPARATOR
Intervention: Passive cycling
Number of subjects: 0
Study 22254404 — intervention group
Group type: COMPARATOR
Intervention: Normal cycling (able-bodied controls)
Number of subjects: 0
Study 19853695 — intervention group
Group type: EXPERIMENTAL
Intervention: AE + IMT
Number of subjects: 24
Study 19853695 — intervention group
Group type: COMPARATOR
Intervention: AE
Number of subjects: 24
Study 16702490 — intervention group
Group type: COMPARATOR
Intervention: 4 mg perindopril
Number of subjects: 57
Study 16702490 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 mg perindopril
Number of subjects: 57
Study 15381507 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifactorial falls prevention programme including 3 months gait and balance training, medication review, podiatry and optometry
Number of subjects: 196
Study 15381507 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 196
Study 15381507 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 196
Study 12934982 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram (mean dose of 57.9 mg/day)
Number of subjects: 38
Study 12934982 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 10220007 — intervention group
Group type: EXPERIMENTAL
Intervention: Executive dysfunction
Number of subjects: 26
Study 10220007 — intervention group
Group type: EXPERIMENTAL
Intervention: Disinhibition of responses
Number of subjects: 26
Study 10220007 — intervention group
Group type: EXPERIMENTAL
Intervention: Motor dyscoordination
Number of subjects: 26
Study 10220007 — intervention group
Group type: EXPERIMENTAL
Intervention: Executive and motor deficits
Number of subjects: 26
Study 7540231 — intervention group
Group type: EXPERIMENTAL
Intervention: Fresenius MTS C (Cuprophane)
Number of subjects: 0
Study 7540231 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospal AN 69 (Polyacrylonitrile)
Number of subjects: 0
Study 7540231 — intervention group
Group type: COMPARATOR
Intervention: CP capillaries
Number of subjects: 0
Study 7540231 — intervention group
Group type: COMPARATOR
Intervention: PA membranes
Number of subjects: 0
Study 2371424 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose inhaled therapy (salbutamol and beclomethasone dipropionate)
Number of subjects: 160
Study 2371424 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of inhaled steroids and beta agonist
Number of subjects: 160
Study 665977 — intervention group
Group type: EXPERIMENTAL
Intervention: 18-gauge polypropylene cannula
Number of subjects: 148
Study 665977 — intervention group
Group type: EXPERIMENTAL
Intervention: 20-gauge Teflon cannula
Number of subjects: 148
Study 31635907 — intervention group
Group type: EXPERIMENTAL
Intervention: Locking plates (VariAx™ - StrykerⓇ)
Number of subjects: 105
Study 31635907 — intervention group
Group type: COMPARATOR
Intervention: Non-locking plates (VIVES™ - StrykerⓇ)
Number of subjects: 105
Study 27353449 — intervention group
Group type: EXPERIMENTAL
Intervention: PriCARE
Number of subjects: 120
Study 26725291 — intervention group
Group type: EXPERIMENTAL
Intervention: Telepsychiatry (N=20)
Number of subjects: 71
Study 26725291 — intervention group
Group type: COMPARATOR
Intervention: Control (In-person psychiatric sessions, N=40)
Number of subjects: 71
Study 24460668 — intervention group
Group type: EXPERIMENTAL
Intervention: CLP 7.5 g/day
Number of subjects: 25
Study 24460668 — intervention group
Group type: EXPERIMENTAL
Intervention: CLP 15.0 g/day
Number of subjects: 25
Study 24460668 — intervention group
Group type: EXPERIMENTAL
Intervention: CLP 25.0 g/day
Number of subjects: 25
Study 24460668 — intervention group
Group type: EXPERIMENTAL
Intervention: CLP 15.0 g/day under fasting conditions
Number of subjects: 25
Study 24460668 — intervention group
Group type: COMPARATOR
Intervention: Control (untreated cohort)
Number of subjects: 25
Study 21499182 — intervention group
Group type: EXPERIMENTAL
Intervention: Cooling with temperatures <32.0°C during induction (n = 33)
Number of subjects: 101
Study 21499182 — intervention group
Group type: EXPERIMENTAL
Intervention: Cooling with temperatures <32.0°C during maintenance (n = 10)
Number of subjects: 101
Study 21499182 — intervention group
Group type: COMPARATOR
Intervention: All other cooled infants (n = 58)
Number of subjects: 101
Study 19932775 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination lipid therapy
Number of subjects: 445
Study 19932775 — intervention group
Group type: EXPERIMENTAL
Intervention: LDL cholesterol-lowering and HDL cholesterol-increasing therapies
Number of subjects: 445
Study 17241666 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitomycin C (0.4 mg/ml) eyedrops, 1 drop 4 times a day for 3 weeks
Number of subjects: 48
Study 17241666 — intervention group
Group type: COMPARATOR
Intervention: Placebo, 1 drop 4 times a day for 3 weeks
Number of subjects: 48
Study 17241666 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitomycin C (0.4 mg/ml) eyedrops
Number of subjects: 48
Study 17241666 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 15717519 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% HES solution, 5-6 ml/kg
Number of subjects: 42
Study 15717519 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% HES solution, 5-6 ml/kg and 1.5% reamberin solution, 5 ml/kg
Number of subjects: 42
Study 15717519 — intervention group
Group type: COMPARATOR
Intervention: Physiological single pregnancy (control group)
Number of subjects: 42
Study 12092991 — intervention group
Group type: EXPERIMENTAL
Intervention: Fuji Bond LC (FBLC) resin‐modified glass‐ionomer bonding system
Number of subjects: 0
Study 12092991 — intervention group
Group type: EXPERIMENTAL
Intervention: FBLC with light-curing
Number of subjects: 0
Study 12092991 — intervention group
Group type: EXPERIMENTAL
Intervention: FBLC without light-curing (co-curing)
Number of subjects: 0
Study 12092991 — intervention group
Group type: EXPERIMENTAL
Intervention: Advanced fluorescent imaging of FBLC
Number of subjects: 0
Study 12092991 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of HEMA in the matrix of FBLC
Number of subjects: 0
Study 9817522 — intervention group
Group type: EXPERIMENTAL
Intervention: Levofloxacin 500 mg twice daily
Number of subjects: 619
Study 9817522 — intervention group
Group type: COMPARATOR
Intervention: Ceftriaxone 4 g i.v. once daily
Number of subjects: 619
Study 7711691 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery
Number of subjects: 129
Study 7711691 — intervention group
Group type: COMPARATOR
Intervention: Open surgery
Number of subjects: 129
Study 7711691 — intervention group
Group type: EXPERIMENTAL
Intervention: Both laparoscopic and open surgery
Number of subjects: 129
Study 29672731 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunct AF surgery (ablation)
Number of subjects: 352
Study 26455498 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone genetic counseling (TC)
Number of subjects: 554
Study 26455498 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 554
Study 24929927 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-compassion
Number of subjects: 48
Study 24929927 — intervention group
Group type: COMPARATOR
Intervention: Waiting condition
Number of subjects: 48
Study 24929927 — intervention group
Group type: COMPARATOR
Intervention: Reappraisal
Number of subjects: 48
Study 24929927 — intervention group
Group type: COMPARATOR
Intervention: Acceptance
Number of subjects: 48
Study 24929927 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-compassion and Reappraisal
Number of subjects: 48
Study 23750991 — intervention group
Group type: EXPERIMENTAL
Intervention: Biannual ultrasonography
Number of subjects: 163
Study 23750991 — intervention group
Group type: COMPARATOR
Intervention: Yearly CT
Number of subjects: 163
Study 19881394 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrient-enriched formula without extra energy
Number of subjects: 102
Study 19881394 — intervention group
Group type: COMPARATOR
Intervention: Standard formula
Number of subjects: 102
Study 19881394 — intervention group
Group type: COMPARATOR
Intervention: Unfortified human milk
Number of subjects: 102
Study 18676384 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% levobupivacaine (15 mg)
Number of subjects: 60
Study 18676384 — intervention group
Group type: COMPARATOR
Intervention: 0.75% levobupivacaine (15 mg)
Number of subjects: 60
Study 16537671 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP) treatment for 3 months
Number of subjects: 10
Study 14518700 — intervention group
Group type: EXPERIMENTAL
Intervention: Indinavir/ritonavir 800/100 mg with food
Number of subjects: 9
Study 14518700 — intervention group
Group type: COMPARATOR
Intervention: Indinavir/ritonavir 800/100 mg on an empty stomach
Number of subjects: 9
Study 10740135 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamifiban bolus and infusion
Number of subjects: 5228
Study 10740135 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5228
Study 8922765 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal scopolamine
Number of subjects: 85
Study 8922765 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron
Number of subjects: 85
Study 8922765 — intervention group
Group type: COMPARATOR
Intervention: Control group (perimenstrual group)
Number of subjects: 85
Study 1558466 — intervention group
Group type: EXPERIMENTAL
Intervention: Half-dose maintenance of imipramine for 12 months
Number of subjects: 0
Study 1558466 — intervention group
Group type: COMPARATOR
Intervention: Acute-phase treatment with imipramine
Number of subjects: 0
Study 3894101 — intervention group
Group type: EXPERIMENTAL
Intervention: Domperidone (DOM) in group A
Number of subjects: 17
Study 3894101 — intervention group
Group type: EXPERIMENTAL
Intervention: Domperidone (DOM) in group B
Number of subjects: 17
Study 3894101 — intervention group
Group type: COMPARATOR
Intervention: Placebo in group A
Number of subjects: 17
Study 3894101 — intervention group
Group type: COMPARATOR
Intervention: Placebo in group B
Number of subjects: 17
Study 30089075 — intervention group
Group type: COMPARATOR
Intervention: Placebo group (no prenatal or postpartum vitamin D supplementation)
Number of subjects: 1164
Study 30089075 — intervention group
Group type: EXPERIMENTAL
Intervention: Prenatal 4200 IU group
Number of subjects: 1164
Study 30089075 — intervention group
Group type: EXPERIMENTAL
Intervention: Prenatal 16,800 IU group
Number of subjects: 1164
Study 30089075 — intervention group
Group type: EXPERIMENTAL
Intervention: Prenatal 28,000 IU group
Number of subjects: 1164
Study 30089075 — intervention group
Group type: EXPERIMENTAL
Intervention: Prenatal and postpartum 28,000 IU group
Number of subjects: 1164
Study 28399909 — intervention group
Group type: EXPERIMENTAL
Intervention: MyPlan mobile app (experimental intervention)
Number of subjects: 546
Study 28399909 — intervention group
Group type: COMPARATOR
Intervention: Safety plan on paper (Treatment as Usual, control)
Number of subjects: 546
Study 26263592 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced oral health promotion program with toothpaste containing 1,450 ppm F‐ and 1.5% arginine
Number of subjects: 3706
Study 26263592 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced oral health promotion program with toothpaste containing 1,450 ppm F‐ and 1.5% arginine in cooperative schools
Number of subjects: 3706
Study 26263592 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 3706
Study 23857539 — intervention group
Group type: EXPERIMENTAL
Intervention: 200‐microgram misoprostol vaginal insert
Number of subjects: 1358
Study 23857539 — intervention group
Group type: COMPARATOR
Intervention: 10‐mg dinoprostone vaginal insert
Number of subjects: 1358
Study 21092829 — intervention group
Group type: EXPERIMENTAL
Intervention: Know & Go! slide presentation
Number of subjects: 64
Study 21092829 — intervention group
Group type: EXPERIMENTAL
Intervention: Know & Go! program
Number of subjects: 64
Study 17419779 — intervention group
Group type: EXPERIMENTAL
Intervention: Evidence-based practice
Number of subjects: 0
Study 17419779 — intervention group
Group type: EXPERIMENTAL
Intervention: Reflective practice
Number of subjects: 0
Study 17419779 — intervention group
Group type: COMPARATOR
Intervention: Hierarchy of evidence
Number of subjects: 0
Study 16046015 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone 450 mg IV bolus
Number of subjects: 100
Study 16046015 — intervention group
Group type: COMPARATOR
Intervention: Digoxin 0.6 mg IV bolus
Number of subjects: 100
Study 12819556 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone Replacement Therapy (HRT)
Number of subjects: 46
Study 12819556 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen-Only Replacement Therapy (ERT)
Number of subjects: 46
Study 12819556 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 10494188 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose chemotherapy with hematopoietic blood stem cell support
Number of subjects: 0
Study 8889439 — intervention group
Group type: EXPERIMENTAL
Intervention: Local, intra-arterial infusion of insulin (0.3 mU dL-1 forearm volume min-1 for 180 min)
Number of subjects: 20
Study 8889439 — intervention group
Group type: EXPERIMENTAL
Intervention: Local, intra-arterial infusion of insulin
Number of subjects: 20
Study 8889439 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined infusion of insulin and glucose (5%, 0.2 mL dL-1 min-1)
Number of subjects: 20
Study 8889439 — intervention group
Group type: COMPARATOR
Intervention: Vehicle control
Number of subjects: 20
Study 1894759 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (120 mg, single dose)
Number of subjects: 20
Study 1894759 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide-5-mononitrate (20 mg, twice daily)
Number of subjects: 20
Study 1894759 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 20
Study 6403716 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiotepa
Number of subjects: 89
Study 6403716 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Number of subjects: 89
Study 6403716 — intervention group
Group type: COMPARATOR
Intervention: Placebo (sterile water)
Number of subjects: 89
Study 30502785 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunitinib
Number of subjects: 1473
Study 30502785 — intervention group
Group type: EXPERIMENTAL
Intervention: Axitinib
Number of subjects: 1473
Study 30502785 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse events
Number of subjects: 1473
Study 30502785 — intervention group
Group type: COMPARATOR
Intervention: Interferon alfa
Number of subjects: 1473
Study 30502785 — intervention group
Group type: COMPARATOR
Intervention: Sorafenib
Number of subjects: 1473
Study 27413125 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycomacropeptide medical foods (GMP‐MFs)
Number of subjects: 30
Study 27413125 — intervention group
Group type: COMPARATOR
Intervention: Amino acid medical foods (AA‐MFs)
Number of subjects: 30
Study 25078929 — intervention group
Group type: EXPERIMENTAL
Intervention: Semirigid fiberglass (SRF)
Number of subjects: 30
Study 25078929 — intervention group
Group type: COMPARATOR
Intervention: Plaster of Paris (POP)
Number of subjects: 30
Study 23895557 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose ethanol (target BrAC = 40 mg%)
Number of subjects: 180
Study 23895557 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose ethanol (target BrAC = 100 mg%)
Number of subjects: 180
Study 23895557 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 180
Study 21066889 — intervention group
Group type: EXPERIMENTAL
Intervention: Zhikang Granule (ZKG)
Number of subjects: 45
Study 21066889 — intervention group
Group type: COMPARATOR
Intervention: Simvastatin
Number of subjects: 45
Study 18455536 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacrocolpopexy surgery
Number of subjects: 301
Study 16552630 — intervention group
Group type: EXPERIMENTAL
Intervention: pioglitazone
Number of subjects: 2408
Study 16552630 — intervention group
Group type: COMPARATOR
Intervention: metformin
Number of subjects: 2408
Study 16552630 — intervention group
Group type: COMPARATOR
Intervention: sulfonylurea
Number of subjects: 2408
Study 15182402 — intervention group
Group type: EXPERIMENTAL
Intervention: Strong soup with red pepper
Number of subjects: 16
Study 15182402 — intervention group
Group type: EXPERIMENTAL
Intervention: Strong capsules with red pepper
Number of subjects: 16
Study 15182402 — intervention group
Group type: COMPARATOR
Intervention: Moderate soup with red pepper
Number of subjects: 16
Study 15182402 — intervention group
Group type: COMPARATOR
Intervention: Placebo soup
Number of subjects: 16
Study 15182402 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsules
Number of subjects: 16
Study 11228175 — intervention group
Group type: EXPERIMENTAL
Intervention: Coadministration of ketoconazole (keto) with cyclosporine (CsA)
Number of subjects: 100
Study 9306481 — intervention group
Group type: EXPERIMENTAL
Intervention: DTaP/PRP‐T combined vaccine
Number of subjects: 485
Study 8457525 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 g 13C‐labelled erythritol
Number of subjects: 6
Study 8457525 — intervention group
Group type: COMPARATOR
Intervention: 25 g 13C‐labelled glucose
Number of subjects: 6
Study 8457525 — intervention group
Group type: COMPARATOR
Intervention: 25 g 13C‐labelled lactitol
Number of subjects: 6
Study 8457525 — intervention group
Group type: EXPERIMENTAL
Intervention: In vitro H2 production by faecal flora with erythritol
Number of subjects: 6
Study 3315583 — intervention group
Group type: EXPERIMENTAL
Intervention: APSAC (30U intravenously)
Number of subjects: 85
Study 3315583 — intervention group
Group type: COMPARATOR
Intervention: Streptokinase (250,000U intracoronary)
Number of subjects: 85
Study 25742062 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematic medication review by a clinical pharmacist and clinical pharmacologist
Number of subjects: 108
Study 25742062 — intervention group
Group type: COMPARATOR
Intervention: Usual medication routine (control)
Number of subjects: 108
Study 25742062 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematic medication review
Number of subjects: 108
Study 27117703 — intervention group
Group type: EXPERIMENTAL
Intervention: Complex behavioural change intervention combining motivational interviewing and access to a habit formation mobile application.
Number of subjects: 264
Study 27117703 — intervention group
Group type: COMPARATOR
Intervention: Control arm (details not specified).
Number of subjects: 264
Study 24078198 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril
Number of subjects: 14
Study 24078198 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 23165582 — intervention group
Group type: EXPERIMENTAL
Intervention: Strategy based on changes in dietary vitamin K intake
Number of subjects: 132
Study 23165582 — intervention group
Group type: COMPARATOR
Intervention: Conventional dose adjustment of oral anticoagulants
Number of subjects: 132
Study 23165582 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients achieving oral anticoagulation stability (n = 23)
Number of subjects: 132
Study 20679166 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal midazolam (IN‐MMAD) 0.2 mg/kg (max 10 mg)
Number of subjects: 358
Study 20679166 — intervention group
Group type: COMPARATOR
Intervention: Rectal diazepam (RD) 0.3 to 0.5 mg/kg (max 20 mg)
Number of subjects: 358
Study 18728590 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency thermorhizotomy (RF-TR)
Number of subjects: 100
Study 16463826 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged cerebral ischaemia (PBO2 decrease below 1.1 kPa for at least 30 minutes) in 3 patients
Number of subjects: 14
Study 16463826 — intervention group
Group type: COMPARATOR
Intervention: Brief ICA clipping (maximum duration of 16 minutes) in 11 patients
Number of subjects: 14